Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis.

• Váldodahkkit: Angela Devine (Dahkki), Minnie Parmiter (Dahkki), Cindy S Chu (Dahkki), Germana Bancone (Dahkki), François Nosten (Dahkki), Ric N Price (Dahkki), Yoel Lubell (Dahkki), Shunmay Yeung (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Public Library of Science (PLoS), 2017-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

BACKGROUND:Primaquine is the only licensed antimalarial for the radical cure of Plasmodium vivax infections. Many countries, however, do not administer primaquine due to fear of hemolysis in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency. In other settings, primaquine is given withou...